Scarica l'app Stockscreener
169.73
0.23%
0.39
Dopo l'orario di chiusura:
168.00
-1.73
-1.02%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Perché AZN Giù?
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Astrazeneca Plc Borsa (AZN) Ultime notizie
AZN Investors Have Opportunity to Join AstraZeneca PLC Fraud Investigation with the Schall Law Firm - lincolnjournal.com
AstraZeneca stock steadies as oncology and vaccines underpin earnings momentum - Ad-hoc-news.de
Jefferies says September lung data can offset AstraZeneca trial failure - Proactive financial news
London Deal Activity Keeps Healthcare Stocks In Focus As AstraZeneca (LSE:AZN) Sets The Tone - Kalkine Media
Stay Ahead of the Game With Astrazeneca (AZN) Q2 Earnings: Wall Street's Insights on Key Metrics - Yahoo Finance UK
Royalty Pharma acquires royalty stake in AstraZeneca drug By Investing.com - Investing.com Canada
Royalty Pharma acquires royalty stake in AstraZeneca drug - Investing.com
Royalty Pharma acquires royalty interest in AstraZeneca’s cliramitug for up to $425 million from Neurimmune - The Manila Times
ASTRAZENECA : Jefferies gives a Buy rating - marketscreener.com
AstraZeneca stock trades steady as oncology and cardiovascular portfolio underpin growth - Ad-hoc-news.de
Earnings Preview: AstraZeneca to Report Financial Results on July 27 - 富途牛牛
AstraZeneca (AZN) Faces Changes Amid New U.S. Drug Tariff Regula - GuruFocus
AstraZeneca stock trades steady as oncology and vaccines underpin growth - Ad-hoc-news.de
PD-1 and PD-L1 Inhibitors Clinical Trial Pipeline Analysis Demonstrates 180+ Key Companies on the Horizon Expected to Transform the Oncology Space | DelveInsight - GlobeNewswire Inc.
AstraZeneca stock holds as earnings and pipeline milestones support valuation - Ad-hoc-news.de
AstraZeneca stock trades steady as oncology revenue supports 2025 outlook - Ad-hoc-news.de
ASTRAZENECA : JP Morgan gives a Buy rating - marketscreener.com
What Is Keeping AstraZeneca (LSE:AZN) At The Centre Of The Pharma Conversation? - Kalkine Media
AstraZeneca stock steadies as oncology growth supports guidance after latest quarterly update - Ad-hoc-news.de
Astrazeneca (AZN) Falls More Steeply Than Broader Market: What Investors Need to Know - Yahoo Finance
AstraZeneca stock trades steadily as oncology and cardiovascular pipeline supports long term growth - Ad-hoc-news.de
Bronstein, Gewirtz & Grossman, LLC Is Investigating AstraZeneca PLC (AZN) And Encourages Investors to Connect - The National Law Review
AstraZeneca slips Monday, underperforms market - MarketWatch
AstraZeneca stock trades steadily as oncology and rare disease growth underpin earnings - Ad-hoc-news.de
What Is Putting AstraZeneca (LSE:AZN) At The Centre Of The Pharma Conversation? - Kalkine Media
AstraZeneca stock trades around recent highs as oncology growth supports valuation - Ad-hoc-news.de
AstraZeneca highlights rare diseases in $80bn revenue push - Financial Times
AstraZeneca PLC (AZN.L) Investor Outlook: Assessing a 25% Upside Potential Amid Robust Revenue Growth - DirectorsTalk Interviews
AstraZeneca stock steady as recent earnings and pipeline progress frame investor debate - ad-hoc-news.de
Bronstein, Gewirtz & Grossman, LLC Is Investigating AstraZeneca PLC (AZN) And Encourages Stockholders to Connect - Stockhouse
AstraZeneca’s Fresh Cancer Drug Boost: What’s Behind the Latest Share Momentum? - Kalkine Media
AstraZeneca stock holds as investors await fresh evidence - ad-hoc-news.de
AstraZeneca | Pharmaceuticals, Vaccines, & Facts | Britannica Money - Encyclopedia Britannica
AstraZeneca stock steady as oncology and rare disease pipeline supports growth - ad-hoc-news.de
Why Is AstraZeneca (LSE:AZN) Drawing Fresh Attention On Oncology Approvals? - Kalkine Media
AstraZeneca PLC (AZN) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
AstraZeneca stock holds on to its earnings momentum - ad-hoc-news.de
AstraZeneca stock trades steady as oncology and rare disease pipeline underpins long term growth - ad-hoc-news.de
AstraZeneca stock trades steadily as oncology and rare disease pipeline underpins long term growth - ad-hoc-news.de
AstraZeneca PLC (AZN) Investigation: Bronstein, Gewirtz & Grossma - The National Law Review
AstraZeneca stock holds as 2025 revenue and profit stay in focus - Ad Hoc News
AstraZeneca stock edges higher as oncology and cardiovascular growth supports outlook - ad-hoc-news.de
Why Is AstraZeneca (LSE:AZN) Back in Healthcare Focus? - Kalkine Media
Why Is AstraZeneca (LSE:AZN) Leading the Blue-Chip Debate? - Kalkine Media
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against AstraZeneca PLC (AZN) and Encourages Stockholders to Learn More About the Investigation - ACCESS Newswire
AstraZeneca Tokenized Stock price today, AZNX to USD chart, marketcap and volume - CryptoSlate
Illumina, Inc., Formation Bio, Astrazeneca, Merck, and Eli Lilly and Company Expand Billion Cell Atlas Alliance with New Ai Drug Developers - marketscreener.com
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of AstraZeneca PLC- AZN - PR Newswire
Attractive Growth Profile Positions AstraZeneca PLC (AZN) as an Investment Bet - Yahoo Finance
What AstraZeneca (LSE:AZN) Says About The Mood Around Healthcare Stocks - Kalkine Media
Why Is AstraZeneca (LSE:AZN) Holding Firm Near Record Highs? - Kalkine Media
AZN Stock Quote Price and Forecast - CNN
Bronstein, Gewirtz & Grossman, LLC Encourages AstraZeneca PLC (AZN) Investors to Inquire about Securities Investigation - ACCESS Newswire
AstraZeneca’s Oncology Engine Keeps Running Despite Wainua Setback (NYSE:AZN) - Seeking Alpha
Bronstein, Gewirtz & Grossman, LLC Encourages AstraZeneca PLC (AZ - The National Law Review
AstraZeneca rises Wednesday, outperforms market - MarketWatch
AstraZeneca pays up to $1.5bn for lung cancer drug - BioXconomy
ASTRAZENECA : Deutsche Bank reiterates its Sell rating - marketscreener.com
AstraZeneca pays up to $1.5bn to license Dizal Pharma’s lung cancer drug - Pharmaceutical Technology
Is AstraZeneca Quietly Rewriting Its Regulatory Story This Week? - Kalkine Media
AstraZeneca slides Tuesday, underperforms market - MarketWatch
Astrazeneca nabs PDE3/4 inhibitor for COPD in $2.1B Sino deal - BioWorld News
AstraZeneca to license lung cancer drug from China's Dizal Pharmaceutical - Reuters
AstraZeneca To Acquire Lung Cancer Drug License For $1.5B - Law360
AstraZeneca stock holds steady as investors wait for a catalyst - Ad-hoc-news.de
AstraZeneca Secures Licensing Deal for Zegfrovy (AZN) - GuruFocus
AstraZeneca (NASDAQ: AZN) signs global Zegfrovy lung cancer deal - Stock Titan
0.51%
0.96%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):